Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACIU NASDAQ:AVDL NASDAQ:MTEM NASDAQ:VSTM NASDAQ:XBIT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACIUAC Immune$2.04-3.3%$1.85$1.43▼$4.26$204.84M1.62143,252 shs86,216 shsAVDLAvadel Pharmaceuticals$9.61-1.6%$9.26$6.38▼$17.30$929.66M1.421.23 million shs760,168 shsMTEMMolecular Templates$0.00$0.00▼$1.59$1K1.535.34 million shsN/AVSTMVerastem$4.68-1.3%$6.16$2.10▼$9.10$257.16M0.711.28 million shs1.21 million shsXBITXBiotech$2.83-4.4%$2.87$2.50▼$8.32$86.29M0.9867,967 shs57,784 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACIUAC Immune+1.44%+2.43%-4.09%+35.26%-38.84%AVDLAvadel Pharmaceuticals+2.30%+9.47%-4.50%+27.21%-39.39%MTEMMolecular Templates0.00%0.00%0.00%0.00%-99.99%VSTMVerastem-1.46%-0.42%-22.55%+2.16%+73.63%XBITXBiotech-3.27%-6.48%+1.72%-9.76%-52.79%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACIUAC Immune2.9585 of 5 stars3.53.00.00.03.70.80.6AVDLAvadel Pharmaceuticals2.7154 of 5 stars3.53.00.00.01.91.70.6MTEMMolecular TemplatesN/AN/AN/AN/AN/AN/AN/AN/AVSTMVerastem2.6301 of 5 stars3.53.00.00.00.82.50.6XBITXBiotech0.4986 of 5 stars0.00.00.00.02.62.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACIUAC Immune 3.00Buy$12.00488.24% UpsideAVDLAvadel Pharmaceuticals 3.00Buy$18.1789.04% UpsideMTEMMolecular Templates 0.00N/AN/AN/AVSTMVerastem 3.00Buy$13.38185.79% UpsideXBITXBiotech 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest MTEM, ACIU, VSTM, XBIT, and AVDL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/25/2025VSTMVerastemRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$16.00 ➝ $12.005/9/2025VSTMVerastemHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$10.00 ➝ $14.005/8/2025AVDLAvadel PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$19.00 ➝ $19.005/1/2025ACIUAC ImmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $12.00(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACIUAC Immune$31.02M6.60N/AN/A$1.29 per share1.58AVDLAvadel Pharmaceuticals$194.45M4.78N/AN/A$0.77 per share12.48MTEMMolecular Templates$23.48M0.00N/AN/A$0.78 per share0.00VSTMVerastem$10M25.72N/AN/A($0.65) per share-7.20XBITXBiotech$4.01M21.52N/AN/A$5.98 per share0.47Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACIUAC Immune-$57.83M-$0.58N/AN/AN/A-177.79%-44.60%-22.25%8/5/2025 (Estimated)AVDLAvadel Pharmaceuticals-$48.83M-$0.27N/A160.17N/A-13.58%-36.07%-16.30%8/6/2025 (Estimated)MTEMMolecular Templates-$8.12M-$2.70N/AN/AN/A-61.35%-260.50%-46.90%N/AVSTMVerastem-$130.64M-$3.20N/AN/AN/AN/A-2,003.62%-127.97%8/6/2025 (Estimated)XBITXBiotech-$38.53M-$1.29N/A∞N/AN/A-21.14%-19.55%8/11/2025 (Estimated)Latest MTEM, ACIU, VSTM, XBIT, and AVDL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025ACIUAC Immune-$0.18N/AN/AN/A$1.98 millionN/A5/14/2025Q1 2025XBITXBiotechN/A-$0.36N/A-$0.36N/AN/A5/13/2025Q1 2025VSTMVerastem-$0.72-$0.96-$0.24-$0.96$0.10 millionN/A5/7/2025Q1 2025AVDLAvadel Pharmaceuticals-$0.07-$0.05+$0.02-$0.05$50.57 million$52.51 million4/30/2025Q1 2025ACIUAC Immune-$0.22-$0.21+$0.01-$0.21$1.99 million$1.12 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACIUAC ImmuneN/AN/AN/AN/AN/AAVDLAvadel PharmaceuticalsN/AN/AN/AN/AN/AMTEMMolecular TemplatesN/AN/AN/AN/AN/AVSTMVerastemN/AN/AN/AN/AN/AXBITXBiotechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACIUAC ImmuneN/A1.531.53AVDLAvadel PharmaceuticalsN/A2.732.33MTEMMolecular TemplatesN/A1.561.56VSTMVerastemN/A3.503.50XBITXBiotechN/A29.1529.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACIUAC Immune51.36%AVDLAvadel Pharmaceuticals69.19%MTEMMolecular Templates95.47%VSTMVerastem88.37%XBITXBiotech55.70%Insider OwnershipCompanyInsider OwnershipACIUAC Immune4.60%AVDLAvadel Pharmaceuticals5.20%MTEMMolecular Templates13.90%VSTMVerastem2.10%XBITXBiotech33.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACIUAC Immune140100.41 million95.79 millionOptionableAVDLAvadel Pharmaceuticals7096.74 million91.71 millionOptionableMTEMMolecular Templates2606.58 million5.67 millionNo DataVSTMVerastem5054.95 million53.80 millionOptionableXBITXBiotech10030.49 million20.40 millionOptionableMTEM, ACIU, VSTM, XBIT, and AVDL HeadlinesRecent News About These CompaniesXBiotech (NASDAQ:XBIT) Share Price Crosses Above 50-Day Moving Average - Here's WhyJuly 4, 2025 | marketbeat.comXBiotech (NASDAQ:XBIT) Share Price Crosses Below 50 Day Moving Average - Here's WhyJune 26, 2025 | marketbeat.comXBiotech (NASDAQ:XBIT) Stock Price Crosses Below 50-Day Moving Average - Here's WhyJune 14, 2025 | marketbeat.comThe Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud InvestigationMarch 2, 2025 | accessnewswire.comAAn Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law FirmMarch 1, 2025 | accessnewswire.comAThe Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud InvestigationFebruary 28, 2025 | accessnewswire.comAAn Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law FirmFebruary 27, 2025 | accessnewswire.comAThe Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud InvestigationFebruary 26, 2025 | accessnewswire.comAAn Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law FirmFebruary 25, 2025 | accessnewswire.comAThe Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud InvestigationFebruary 24, 2025 | accessnewswire.comAAn Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law FirmFebruary 23, 2025 | accessnewswire.comAThe Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud InvestigationFebruary 22, 2025 | accessnewswire.comAAn Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law FirmFebruary 21, 2025 | accessnewswire.comAThe Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud InvestigationFebruary 20, 2025 | accessnewswire.comAThe Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud InvestigationFebruary 18, 2025 | accessnewswire.comAXBiotech Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law FirmFebruary 17, 2025 | accessnewswire.comAThe Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud InvestigationFebruary 16, 2025 | accessnewswire.comAXBiotech Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law FirmFebruary 15, 2025 | accessnewswire.comAThe Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud InvestigationFebruary 14, 2025 | accessnewswire.comAXBiotech Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law FirmFebruary 13, 2025 | accessnewswire.comAThe Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud InvestigationFebruary 12, 2025 | accessnewswire.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeMTEM, ACIU, VSTM, XBIT, and AVDL Company DescriptionsAC Immune NASDAQ:ACIU$2.04 -0.07 (-3.32%) Closing price 04:00 PM EasternExtended Trading$2.05 +0.01 (+0.49%) As of 04:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.Avadel Pharmaceuticals NASDAQ:AVDL$9.61 -0.16 (-1.64%) Closing price 04:00 PM EasternExtended Trading$9.46 -0.15 (-1.51%) As of 05:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.Molecular Templates NASDAQ:MTEMMolecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company develops therapies through its proprietary biologic drug platform technology (ETB). It is also developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.Verastem NASDAQ:VSTM$4.68 -0.06 (-1.27%) Closing price 04:00 PM EasternExtended Trading$4.74 +0.06 (+1.18%) As of 06:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.XBiotech NASDAQ:XBIT$2.83 -0.13 (-4.39%) Closing price 04:00 PM EasternExtended Trading$2.84 +0.01 (+0.35%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Plug Power’s 20% Surge Signals New Commercial Growth Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
